The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The ...

As anticipated, we have seen robust tumor control and ATNM-400 has shown to be well tolerated in preclinical studies, which we believe is due to the precise and potent cell-killing of Ac-225.

But if you've already been diagnosed with prostate cancer, you may need a different test-- for the prostate-specific membrane antigen or PSMA. PSA can show up in cells throughout the body ...

particularly for patients progressing or not well served by the PSMA targeting radiotherapy Pluvicto given its novel target and the potent cell killing ability of the Ac-225 isotope payload.

Actinium Pharmaceuticals Inc. has unveiled ATNM-400, a novel non-PSMA-targeting, first-in-class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope.

He remains symptom-free. The treatment is now approved for more patients. The randomized trial in 468 patients showed that 177 Lu-PSMA-617 prolonged progression-free survival (the period when the ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...